Tearsheet
DYN Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About DYN Interactive Breakdown Better Bets vs. DYN Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Trade Sentinel Investor Videos Industry Resource Links External Quote Links

Dyne Therapeutics (DYN)

Market Price (6/17/2026): $19.19 | Market Cap: $3.2 BilSector: Health Care | Industry: Biotechnology

Dyne Therapeutics (DYN)

Market Price (6/17/2026): $19.19
Market Cap: $3.2 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -27%

Megatrend and thematic drivers
Megatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.

Weak multi-year price returns
2Y Excs Rtn is -81%, 3Y Excs Rtn is -35%

Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 14.63, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13%

Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -471 Mil

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19%

Key risks
DYN key risks include [1] potential clinical trial failures or regulatory delays for its lead candidates in DMD and DM1 and [2] intense competition from established pharmaceutical companies like Sarepta Therapeutics and Roche.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -27%
1 Megatrend and thematic drivers
Megatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.
2 Weak multi-year price returns
2Y Excs Rtn is -81%, 3Y Excs Rtn is -35%
3 Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 14.63, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13%
4 Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
5 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -471 Mil
6 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19%
7 Key risks
DYN key risks include [1] potential clinical trial failures or regulatory delays for its lead candidates in DMD and DM1 and [2] intense competition from established pharmaceutical companies like Sarepta Therapeutics and Roche.

Valuation & Metrics

FYE: 12/31DYN [1]S&P 500 [2]
REVENUE GROWTH
LTM Revenue [3]$0.0 Mil—
FY 2026 Sales$1.0 Mil—
FY 2027 Sales$51.3 Mil—
FY 2026 Sales Growth——
FY 2027 Sales Growth5,050.8%7.8%
EARNINGS
LTM Net Income (GAAP) [3]$-451.7 Mil—
FY 2026 Net Income (Non-GAAP)$-394.6 Mil—
FY 2027 Net Income (Non-GAAP)$-375.2 Mil—
FY 2027 Net Income Growth—15.3%
FY 2026 EPS (Non-GAAP)$-3.08—
FY 2027 EPS (Non-GAAP)$-2.94—
FY 2027 EPS Growth——
VALUATION
FY 2026 P/S3,180.63.3
FY 2027 P/S61.8—
FY 2026 P/E—20.6
FY 2027 P/E——

[1] DYN forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
[2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 6/30/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
[3] LTM = reported trailing-twelve-month actuals (GAAP).
null

AI Analysis | Feedback

MetricValueDateSource
Number of Clinical Programs48272025Link
Number of Preclinical Programs28272025Link
Patients Enrolled in DELIVER Trial (Registrational Expansion Cohort)3211052025Link
Target Enrollment in ACHIEVE Trial (Registrational Expansion Cohort)6011052025Link
FDA Breakthrough Therapy Designations211052025Link

Price Chart

null
No Events

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 6/15/2026

Dyne Therapeutics (DYN) stock has gained about 15% since 2/28/2026 because of the following key factors:

1. Significant advancements in clinical development and regulatory submissions for lead programs.

Dyne Therapeutics achieved key milestones in its Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1) programs. For z-rostudirsen in DMD, the company completed a positive pre-Biologics License Application (BLA) meeting with the FDA and submitted a BLA for U.S. Accelerated Approval in fiscal Q2 2026. Additionally, Dyne initiated the global confirmatory Phase 3 FORZETTO trial for z-rostudirsen in May 2026. In the DM1 program, Dyne initiated the global confirmatory Phase 3 HARMONIA trial for z-basivarsen in March 2026 and successfully completed enrollment of over 60 participants in the registrational expansion cohort of the ACHIEVE trial by fiscal Q2 2026. These updates signal strong progress toward potential market approval and commercialization.

2. Robust financial position with an extended cash runway.

Dyne Therapeutics reported strong fiscal Q1 2026 financial results on May 11, 2026, disclosing cash, cash equivalents, and marketable securities of $972.2 million as of March 31, 2026. This capital is projected to fund operations into fiscal Q1 2028, providing significant financial stability for ongoing research and development and future commercialization efforts. Furthermore, the company reported a narrower net loss of $0.73 per share for fiscal Q1 2026, exceeding analyst expectations of -$0.7808 by 6.51%.

Show more
Updated on 6/15/2026

Dyne Therapeutics (DYN) stock has gained about 15% since 2/28/2026 because of the following key factors:

1. Significant advancements in clinical development and regulatory submissions for lead programs.

Dyne Therapeutics achieved key milestones in its Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1) programs. For z-rostudirsen in DMD, the company completed a positive pre-Biologics License Application (BLA) meeting with the FDA and submitted a BLA for U.S. Accelerated Approval in fiscal Q2 2026. Additionally, Dyne initiated the global confirmatory Phase 3 FORZETTO trial for z-rostudirsen in May 2026. In the DM1 program, Dyne initiated the global confirmatory Phase 3 HARMONIA trial for z-basivarsen in March 2026 and successfully completed enrollment of over 60 participants in the registrational expansion cohort of the ACHIEVE trial by fiscal Q2 2026. These updates signal strong progress toward potential market approval and commercialization.

2. Robust financial position with an extended cash runway.

Dyne Therapeutics reported strong fiscal Q1 2026 financial results on May 11, 2026, disclosing cash, cash equivalents, and marketable securities of $972.2 million as of March 31, 2026. This capital is projected to fund operations into fiscal Q1 2028, providing significant financial stability for ongoing research and development and future commercialization efforts. Furthermore, the company reported a narrower net loss of $0.73 per share for fiscal Q1 2026, exceeding analyst expectations of -$0.7808 by 6.51%.

3. Favorable analyst sentiment and encouraging price targets.

Throughout the specified period, Dyne Therapeutics maintained a positive outlook from Wall Street analysts. As of June 14, 2026, analysts had a consensus "Moderate Buy" rating for the stock. The average price target ranged from $35.00 to $40.00, implying a substantial potential upside from its trading price. This continued strong analyst confidence in Dyne's pipeline and future prospects contributed to the positive stock performance.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 15.7% change in DYN stock from 2/28/2026 to 6/16/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
(LTM values as of)22820266162026Change
Stock Price ($)15.6218.0715.7%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)142165-14.1%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2026 to 6/16/2026
ReturnCorrelation
DYN15.7% 
Market (SPY)9.7%52.2%
Sector (XLV)-4.1%36.2%

Fundamental Drivers

The -17.5% change in DYN stock from 11/30/2025 to 6/16/2026 was primarily driven by a -14.1% change in the company's Shares Outstanding (Mil).
(LTM values as of)113020256162026Change
Stock Price ($)21.9018.07-17.5%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)142165-14.1%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

11/30/2025 to 6/16/2026
ReturnCorrelation
DYN-17.5% 
Market (SPY)10.4%42.6%
Sector (XLV)-2.2%31.1%

Fundamental Drivers

The 51.1% change in DYN stock from 5/31/2025 to 6/16/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
(LTM values as of)53120256162026Change
Stock Price ($)11.9618.0751.1%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)110165-33.4%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

5/31/2025 to 6/16/2026
ReturnCorrelation
DYN51.1% 
Market (SPY)28.8%34.9%
Sector (XLV)17.4%25.2%

Fundamental Drivers

The 38.7% change in DYN stock from 5/31/2023 to 6/16/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
(LTM values as of)53120236162026Change
Stock Price ($)13.0318.0738.7%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)56165-65.9%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

5/31/2023 to 6/16/2026
ReturnCorrelation
DYN38.7% 
Market (SPY)86.6%31.8%
Sector (XLV)25.8%25.3%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
DYN Return-43%-3%15%77%-17%-4%-11%
Peers Return43%-20%3%78%-33%-21%11%
S&P 500 Return27%-19%24%23%16%10%101%

Monthly Win Rates [3]
DYN Win Rate17%50%42%67%42%33% 
Peers Win Rate46%50%46%58%75%23% 
S&P 500 Win Rate75%42%67%75%67%50% 

Max Drawdowns [4]
DYN Max Drawdown-59%-64%-56%-50%-73%-25% 
Peers Max Drawdown-41%-46%-34%-26%-59%-39% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ATYR, AVLN, CNXU, COAG.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/16/2026 (YTD)

How Low Can It Go

EventDYNS&P 500
2025 US Tariff Shock
  % Loss-50.7%-18.8%
  % Gain to Breakeven102.9%23.1%
  Time to Breakeven58 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-36.1%-9.5%
  % Gain to Breakeven56.5%10.5%
  Time to Breakeven19 days24 days
2023 SVB Regional Banking Crisis
  % Loss-36.0%-6.7%
  % Gain to Breakeven56.2%7.1%
  Time to Breakeven23 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-64.5%-24.5%
  % Gain to Breakeven181.4%32.4%
  Time to Breakeven97 days427 days

Compare to VRTX, ATYR, AVLN, CNXU, COAG

In The Past

Dyne Therapeutics's stock fell -50.7% during the 2025 US Tariff Shock. Such a loss loss requires a 102.9% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventDYNS&P 500
2025 US Tariff Shock
  % Loss-50.7%-18.8%
  % Gain to Breakeven102.9%23.1%
  Time to Breakeven58 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-36.1%-9.5%
  % Gain to Breakeven56.5%10.5%
  Time to Breakeven19 days24 days
2023 SVB Regional Banking Crisis
  % Loss-36.0%-6.7%
  % Gain to Breakeven56.2%7.1%
  Time to Breakeven23 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-64.5%-24.5%
  % Gain to Breakeven181.4%32.4%
  Time to Breakeven97 days427 days

Compare to VRTX, ATYR, AVLN, CNXU, COAG

In The Past

Dyne Therapeutics's stock fell -50.7% during the 2025 US Tariff Shock. Such a loss loss requires a 102.9% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Dyne Therapeutics (DYN)

```html

Dyne Therapeutics, Inc. is a biotechnology company committed to advancing new therapeutic options for individuals suffering from genetically driven muscle diseases. Headquartered in Waltham, Massachusetts, the company focuses on tackling the underlying causes of these debilitating conditions rather than just managing symptoms.

The core of Dyne's approach is its proprietary FORCE platform, which is designed to deliver disease-modifying therapeutics directly to muscle tissue. The company's development programs primarily target severe genetic disorders such as myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Beyond these key areas, Dyne is also exploring treatments for a range of other rare skeletal muscle, cardiac muscle, and metabolic muscle diseases.

Essentially, Dyne Therapeutics serves the market of patients afflicted with these specific, often underserved, genetic muscle conditions. By leveraging its specialized platform, the company aims to provide innovative and targeted treatments that can significantly alter the course of these diseases, ultimately improving the lives of those affected.

```

AI Analysis | Feedback

Here are a few analogies for Dyne Therapeutics (DYN):

  • Vertex Pharmaceuticals for muscle diseases.

  • Moderna, but applying a specialized drug delivery platform to genetic muscle diseases.

AI Analysis | Feedback

  • Therapeutics for Myotonic Dystrophy Type 1 (DM1): Drug candidates in development to treat myotonic dystrophy type 1, a genetically driven muscle disease.
  • Therapeutics for Duchenne Muscular Dystrophy (DMD): Drug candidates in development to treat Duchenne muscular dystrophy, a severe muscle-wasting disease.
  • Therapeutics for Facioscapulohumeral Dystrophy (FSHD): Drug candidates in development to treat facioscapulohumeral dystrophy, a progressive muscle weakness and wasting condition.
  • Therapeutics for Rare Skeletal Muscle Diseases: Programs focused on developing treatments for various other rare diseases affecting skeletal muscles.
  • Therapeutics for Cardiac and Metabolic Muscle Diseases: Programs focused on developing treatments for muscle diseases impacting cardiac function and metabolism.

AI Analysis | Feedback

As a biotechnology company focused on advancing therapeutics for genetically driven muscle diseases, Dyne Therapeutics (DYN) is primarily engaged in research, development, and clinical trials for its drug candidates. At this stage, the company does not have major customers in the traditional sense, as its therapeutic products are still in development and have not yet been commercialized for sale to individuals or other companies.

AI Analysis | Feedback

null

AI Analysis | Feedback

John Cox

President and Chief Executive Officer
John Cox was appointed President and Chief Executive Officer of Dyne Therapeutics on March 25, 2024. Prior to joining Dyne, he served as CEO of Bioverativ Inc., a spin-off from Biogen Inc., which was subsequently acquired by Sanofi in 2018. Mr. Cox also held the CEO position at Repertoire Immune Medicines and its predecessor, Torque Therapeutics. Over a 14-year tenure at Biogen, he held various senior roles, including Executive Vice President of Global Commercial & Technical Operations, and was instrumental in orchestrating the spin-out of Biogen's hematology business to form Bioverativ. He brings extensive experience in rare disease commercialization and global operations to Dyne.

Erick J. Lucera

Chief Financial Officer
Erick J. Lucera was appointed Chief Financial Officer of Dyne Therapeutics, effective March 31, 2025. He brings over three decades of financial, operational, and investment experience in the life science industry. Before joining Dyne, Mr. Lucera served as CFO at Editas Medicine. Previously, he was CFO of AVEO Pharmaceuticals, where he played a key role in its transition from a clinical-stage company to commercialization and its acquisition by LG Chem. His background also includes executive positions as CFO, treasurer, and secretary at Valeritas and Viventia Bio, and Vice President of Corporate Development at Aratana Therapeutics. Mr. Lucera also spent 15 years in investment management as a healthcare analyst.

Ranjan (Ron) Batra, Ph.D.

Chief Scientific Officer
Ranjan (Ron) Batra, Ph.D., was appointed Chief Scientific Officer of Dyne Therapeutics in April 2025. Dr. Batra joined Dyne from Lexeo Therapeutics, where he was the Vice President of Research and Translation. He previously served as Senior Vice President of R&D at LocanaBio, where he advanced RNA-targeted therapies for rare disorders, including Duchenne muscular dystrophy and myotonic dystrophy. Dr. Batra is recognized as a leading expert in RNA biology and therapeutics.

Oxana Beskrovnaya, Ph.D.

Chief Innovation Officer
Oxana Beskrovnaya, Ph.D., transitioned to the role of Chief Innovation Officer at Dyne Therapeutics, effective April 28, 2025, where she is responsible for driving the company's comprehensive innovation strategy. Prior to this, she served as Dyne's Chief Scientific Officer, a position she was appointed to in June 2021 after serving as Senior Vice President, Head of Research since January 2020. Before joining Dyne, Dr. Beskrovnaya was Head of Musculoskeletal and Renal Research in Sanofi's rare disease and neurological unit, where she advanced a pipeline of drug candidates.

Vikram (Vik) Ranade, PhD

Chief Business Officer
Vikram (Vik) Ranade, PhD, was appointed Chief Business Officer of Dyne Therapeutics in April 2025. In this role, Dr. Ranade leads business development, corporate strategy, and strategic partnerships for the company, supporting its late-stage clinical and commercialization plans.

AI Analysis | Feedback

The key risks for Dyne Therapeutics (symbol: DYN), a biotechnology company focused on developing therapeutics for genetically driven muscle diseases, are primarily associated with the inherent uncertainties of drug development and the financial demands of a clinical-stage company.

  1. Clinical Trial Failures: Dyne Therapeutics' success is heavily dependent on positive data from its ongoing and future clinical trials for lead candidates like DYNE-251 for Duchenne muscular dystrophy (DMD) and DYNE-101 for myotonic dystrophy type 1 (DM1). Adverse or unclear results, unexpected safety issues, or failure to meet efficacy endpoints could significantly impact the company's valuation and prospects.
  2. Regulatory Delays and Challenges: The process for obtaining regulatory approvals from agencies like the FDA is complex and often unpredictable. Delays in receiving approval, or even in filing for approval, for its product candidates could deplete Dyne's cash reserves faster than anticipated. The interpretation of clinical trial data by regulatory authorities and the acceptance of Dyne's clinical programs also present significant uncertainties.
  3. Financial Risks and Need for Additional Funding: As a clinical-stage biotechnology company, Dyne Therapeutics currently generates no revenue and incurs substantial operating losses due to extensive research and development costs. While the company has cash reserves, there is a continuous need for significant external funding to sustain its operations and advance its pipeline. If clinical trial timelines shift or expenses increase, future fundraising efforts through equity offerings or debt financing could lead to the dilution of existing shareholders' stakes.

AI Analysis | Feedback

Direct Competition with Advanced Therapies for Shared Indications: Avidity Biosciences (AVID) is developing antibody-oligonucleotide conjugates (AOCs) for genetically driven muscle diseases, a therapeutic approach conceptually similar to Dyne's FORCE platform. Avidity's lead candidate, AOC 1044, is in Phase 3 for Myotonic Dystrophy Type 1 (DM1), a key target for Dyne, whose DYNE-101 is in Phase 1/2. Avidity also has AOC 1020 in Phase 1/2 for Facioscapulohumeral Dystrophy (FSHD), another of Dyne's target indications. This advanced clinical progress by a direct competitor using a similar platform poses a significant threat to Dyne's market position and development timeline for these diseases.

AI Analysis | Feedback

Dyne Therapeutics (NASDAQ: DYN) is focused on developing therapeutics for genetically driven muscle diseases, with programs targeting Myotonic Dystrophy Type 1 (DM1), Duchenne Muscular Dystrophy (DMD), and Facioscapulohumeral Dystrophy (FSHD).

Myotonic Dystrophy Type 1 (DM1)

The global addressable market for Myotonic Dystrophy Type 1 (DM1) is projected to experience significant growth. In 2024, the market was valued at approximately USD 1,550 million and is expected to reach USD 3,204 million by 2032, demonstrating a Compound Annual Growth Rate (CAGR) of 9.5% over the forecast period. Another estimate places the global market at USD 874.39 million in 2023, with a projection to reach around USD 2,789.35 million by 2033, growing at a CAGR of 12.3%. North America accounts for a substantial portion of the global DM1 market, representing 35% of the market share. The U.S. alone had approximately 54,068 diagnosed prevalent cases of Myotonic Dystrophy in 2023, accounting for 51% of the total cases across the seven major markets (7MM: U.S., Germany, Spain, Italy, France, UK, and Japan). DM1 is considered a large, unaddressed market with no approved disease-modifying therapies currently available.

Duchenne Muscular Dystrophy (DMD)

The global Duchenne Muscular Dystrophy (DMD) drug market reached an estimated value of USD 2.3 billion in 2023 and is anticipated to grow to USD 5.5 billion by 2032, with a CAGR of 9.96% from 2024 to 2032. Other reports indicate the global market size for DMD drugs was valued at USD 3.2 billion in 2023 and is projected to reach USD 8.6 billion by 2032, at a CAGR of 11.6%. Another source estimates the global DMD drugs market size at USD 3.47 billion in 2023, with a projection to reach USD 9.91 billion by 2030, exhibiting a higher CAGR of 16.8% from 2024 to 2030. In 2023, the DMD market size across the 7MM was approximately USD 2,150 million. The United States represents the largest market for DMD drugs within the 7MM, with an estimated market size of around USD 1,900 million. North America held the largest revenue share, 45.0%, in the global Duchenne muscular dystrophy drugs market in 2023.

Facioscapulohumeral Dystrophy (FSHD)

The 7 major Facioscapulohumeral Muscular Dystrophy (FSHD) markets had a value of USD 32.2 million in 2024 and are expected to reach USD 61.4 million by 2035, with a CAGR of 6.12% during 2025-2035. A global market report indicates the FSHD market was valued at USD 210 million in 2024 and is projected to reach USD 482 million by 2034, expanding at a CAGR of 8.6% during this period. The United States holds the largest market share for Facioscapulohumeral Muscular Dystrophy, accounting for approximately 80% of the market compared to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan. Conversely, Europe is noted for having the largest patient pool and also representing the largest market for FSHD treatment.

AI Analysis | Feedback

Dyne Therapeutics (DYN), a biotechnology company focused on genetically driven muscle diseases, is poised for future revenue growth over the next 2-3 years through the advancement and potential commercialization of its pipeline products. Key drivers include:

  1. Commercialization of Z-rostudirsen (DYNE-251) for Duchenne Muscular Dystrophy (DMD): Dyne Therapeutics is on track for a Biologics License Application (BLA) filing for U.S. Accelerated Approval of z-rostudirsen in the second quarter of 2026, with a potential commercial launch anticipated in the first quarter of 2027. This represents the most immediate potential revenue stream for the company.
  2. Commercialization of Z-basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1): The company is progressing with its registrational expansion cohort for z-basivarsen, with data expected in mid-2026 to support a potential U.S. Accelerated Approval BLA submission in late 2026. A pivotal Phase 3 HARMONIA trial for z-basivarsen was initiated in March 2026, with a potential commercial launch projected for 2027-2028.
  3. Expansion of the Duchenne Muscular Dystrophy (DMD) Franchise: Beyond z-rostudirsen, Dyne is developing additional preclinical programs targeting other exons (e.g., 53, 45, 44, and 55) for DMD. This expansion could significantly broaden the addressable patient population for their DMD therapies by tripling the market to 4,000-5,000 patients, leveraging the validated FORCE platform.
  4. Advancement of Pipeline Programs for Other Genetically Driven Muscle Diseases: Dyne's FORCE platform is being utilized to advance preclinical programs for other rare neuromuscular disorders, including facioscapulohumeral muscular dystrophy (FSHD) with DYNE-302 and Pompe disease with DYNE-401. Positive preclinical data for DYNE-401 in Pompe disease was highlighted in February 2026, indicating future potential and diversification of their therapeutic portfolio. Continued progress in these programs through clinical development stages would be a driver of future revenue growth.

AI Analysis | Feedback

```html

Share Issuance

  • In December 2025, Dyne Therapeutics closed an upsized underwritten public offering, selling 21,827,549 shares of common stock at $18.44 per share, resulting in gross proceeds of approximately $402.5 million.
  • In July 2025, the company completed a public offering that generated approximately $230 million in gross proceeds.

Inbound Investments

  • In June 2025, Dyne Therapeutics secured a $275 million non-dilutive senior secured term loan facility from Hercules Capital, Inc., with an initial tranche of $100 million funded at closing.
  • The term loan facility includes additional tranches totaling up to $115 million, available upon achieving specific clinical, regulatory, and commercial milestones, and a final tranche of up to $60 million subject to approval.
  • As of December 2025, institutional investors collectively increased their stake in Dyne Therapeutics to 159.84 million shares, representing 138.0% of the company, reflecting a 10.54% quarter-over-quarter increase.

Capital Expenditures

  • Capital expenditures in a recent quarter (Q3 2025) totaled approximately -$19.19 million.
  • Dyne expects its existing cash, cash equivalents, and marketable securities, including proceeds from recent offerings and the term loan, to fund its operating expenses and capital expenditure requirements into the third quarter of 2027. This cash runway was further extended into Q1 2028 based on year-end 2025 cash of $1.1 billion.
  • The primary focus of capital expenditures is to advance its pipeline, particularly late-stage clinical trials for DYNE-101 and DYNE-251, and to build out commercial infrastructure for potential product launches in 2027-2028.
```

Latest Trefis Analyses

Recent Active Movers

Top Gainers

TickerCompanyMkt Cap (B)1W RtnYTD Rtn
FRMIFermi5.040.2%-1.5%
MBXMBX Biosciences1.934.2%27.1%
RXTRackspace Technology1.533.3%539.6%
WDCWestern Digital232.931.6%295.6%
SCZMSantacruz Silver Mining0.730.7%-23.9%
BIOABioage Labs0.929.7%54.9%
VELOVelo3D0.528.9%82.2%
AMCAMC Entertainment1.328.4%59.6%
PGENPrecigen1.728.0%13.6%
AYAAya Gold & Silver3.026.2%46.5%

Top Losers

TickerCompanyMkt Cap (B)1W RtnYTD Rtn
SWMRSwarmer0.7-31.4%33.5%
SMCISuper Micro Computer17.5-28.1%-0.2%
PCTPureCycle Technologies1.5-24.1%-4.7%
FOXAFox22.2-23.4%-28.0%
PRCTPROCEPT BioRobotics1.2-23.2%-29.8%
FOXFox20.3-21.3%-25.8%
MHMcGraw Hill2.0-20.5%-37.5%
NMAXNewsmax1.0-18.7%-3.0%
BANDBandwidth1.6-18.3%235.1%
DANDana3.3-18.0%27.0%

Top Gainers

TickerCompanyMkt Cap (B)1M RtnYTD Rtn
NVRIEnviri1.7287.5%319.3%
APPSDigital Turbine1.1122.7%88.0%
AMCAMC Entertainment1.394.5%59.6%
TWSTTwist Bioscience5.272.8%167.8%
REPLReplimune0.868.2%-9.7%
DELLDell Technologies266.767.0%222.4%
VSHVishay Intertechnology8.262.3%319.3%
GENIGenius Sports1.962.0%-37.7%
HYLNHyliion1.359.1%303.8%
MRVLMarvell Technology239.957.5%228.3%

Top Losers

TickerCompanyMkt Cap (B)1M RtnYTD Rtn
ADCTADC Therapeutics0.2-69.3%-71.8%
VRRMVerra Mobility0.8-61.7%-77.6%
FULCFulcrum Therapeutics0.3-48.3%-69.4%
CDChaince Digital0.4-41.3%-2.0%
PLABPhotronics1.8-39.2%-4.9%
BTGOBitGo0.5-38.8%-70.6%
SATLSatellogic0.9-37.6%228.3%
CELCCelcuity4.8-36.6%-12.5%
PCTPureCycle Technologies1.5-34.9%-4.7%
SOCSable Offshore1.4-34.0%10.8%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Peers to compare with:

Financials

DYNVRTXATYRAVLNCNXUCOAGMedian
NameDyne The.Vertex P.aTyr Pha.Avalyn P.Conexeu .Hemab Th. 
Mkt Price18.07453.170.4528.0712.5225.5121.79
Mkt Cap3.0115.2----59.1
Rev LTM012,218--0-0
Op Inc LTM-4714,662---5--5
FCF LTM-4623,710---4--4
FCF 3Y Avg-3351,977----821
CFO LTM-4424,241---4--4
CFO 3Y Avg-3272,401----1,037

Growth & Margins

DYNVRTXATYRAVLNCNXUCOAGMedian
NameDyne The.Vertex P.aTyr Pha.Avalyn P.Conexeu .Hemab Th. 
Rev Chg LTM-10.1%----10.1%
Rev Chg 3Y Avg-9.9%----9.9%
Rev Chg Q-7.8%----7.8%
QoQ Delta Rev Chg LTM-1.8%----1.8%
Op Inc Chg LTM-18.6%1,214.0%----597.7%
Op Inc Chg 3Y Avg-38.4%364.1%----162.9%
Op Mgn LTM-38.2%----38.2%
Op Mgn 3Y Avg-24.1%----24.1%
QoQ Delta Op Mgn LTM-0.2%----0.2%
CFO/Rev LTM-34.7%----34.7%
CFO/Rev 3Y Avg-21.5%----21.5%
FCF/Rev LTM-30.4%----30.4%
FCF/Rev 3Y Avg-17.7%----17.7%

Valuation

DYNVRTXATYRAVLNCNXUCOAGMedian
NameDyne The.Vertex P.aTyr Pha.Avalyn P.Conexeu .Hemab Th. 
Mkt Cap3.0115.2----59.1
P/S-9.4----9.4
P/Op Inc-6.324.7----9.2
P/EBIT-6.822.7----8.0
P/E-6.626.5----10.0
P/CFO-6.727.2----10.2
Total Yield-15.1%3.8%-----5.7%
Dividend Yield0.0%0.0%----0.0%
FCF Yield 3Y Avg-17.7%1.8%-----7.9%
D/E0.10.0----0.0
Net D/E-0.3-0.0-----0.2

Returns

DYNVRTXATYRAVLNCNXUCOAGMedian
NameDyne The.Vertex P.aTyr Pha.Avalyn P.Conexeu .Hemab Th. 
1M Rtn4.5%3.7%-11.2%-5.9%-13.1%-9.1%-7.5%
3M Rtn-3.2%-2.0%-49.2%-4.8%-13.1%-25.0%-8.9%
6M Rtn-7.6%-0.4%-38.9%-4.8%-13.1%-25.0%-10.3%
12M Rtn30.8%0.5%-91.8%-4.8%-13.1%-25.0%-8.9%
3Y Rtn65.0%30.3%-81.7%-4.8%-13.1%-25.0%-8.9%
1M Excs Rtn3.1%2.3%-12.5%-7.3%-14.4%-10.5%-8.9%
3M Excs Rtn-15.0%-13.9%-61.0%-16.7%-24.9%-36.8%-20.8%
6M Excs Rtn-16.2%-9.8%-52.3%-14.8%-23.1%-35.0%-19.7%
12M Excs Rtn-0.3%-26.2%-117.1%-30.5%-38.7%-50.6%-34.6%
3Y Excs Rtn-35.3%-39.1%-154.4%-79.5%-87.8%-99.7%-83.7%

Comparison Analyses

null

Financials

$ Mil | FY: 12/312026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q2
Period End3/31/202612/31/20259/30/20256/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/2023
Filing Date5/11/20263/2/202611/5/20257/28/20255/8/20252/27/202511/12/20248/12/20245/2/20243/5/202410/30/20238/3/2023
Key Financials Quarterly            
Total Revenue000000000000
Ebitda-116-108-105-110-115-89-97-65-69-61-62-66
Operating Income-125-116-114-116-122-97-106-72-69-68-62-67
Net Income-121-112-108-111-115-90-97-65-66-67-60-65
EPS-0.73-0.76-0.76-0.97-1.05-0.88-0.96-0.70-0.81-1.09-0.99-1.08
Key Financials TTM            
Total Revenue TTM000000000000
Ebitda TTM-439-438-419-411-365-319-291-256-258-234-213-193
Operating Income TTM-471-468-449-441-397-344-314-271-266-242-215-195
Net Income TTM-452-446-424-413-367-317-295-258-257-236-208-189
Growth Rates Quarterly            
Total Revenue Growth------------
EBITDA Growth-1.1%-21.5%-8.2%-70.4%-67.0%-45.9%-56.3%2.4%-52.6%-53.6%-47.7%-26.8%
Operating Income Growth-2.4%-19.6%-7.8%-60.9%-76.9%-43.5%-69.7%-7.8%-52.1%-68.6%-47.3%-26.5%
Net Income Growth-4.8%-25.0%-11.2%-70.3%-75.7%-34.4%-61.3%-0.3%-48.6%-71.6%-45.5%-24.1%
Margins Quarterly            
EBITDA Margin------------
Operating Income Margin------------
Net Income Margin------------
Cash & Debt            
Total Cash9721,111792684677642724779454123158208
Total Debt1691691201212324252627272829
Net Debt / (Cash)-803-941-671-563-654-618-699-753-427-96-130-179
Cash Flows Quarterly            
FCF from Operations-145-112-91-95-106-84-75-55-79-35-51-56
Cash Flows TTM            
FCF from Operations TTM-442-403-376-360-320-292-243-219-220-188-182-175
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC-31.7%-32.6%-34.9%-39.1%-45.3%-40.4%-48.7%-36.7%-36.9%-43.1%-42.3%-50.0%
Return on Invested Capital (ROIC) TTM            
ROIC TTM-29.8%-32.8%-34.4%-37.2%-36.8%-35.8%-36.3%-34.5%-35.5%-38.6%-36.5%-36.5%

Segment Financials

Net Income by Segment
$ Mil20252024
Single segment-446-317
Total-446-317


Assets by Segment
$ Mil20242023202220212020
Single segment691165306426353
Total691165306426353


Price Behavior

Price Behavior
Market Price$18.07 
Market Cap ($ Bil)3.0 
First Trading Date09/17/2020 
Distance from 52W High-25.6% 
   50 Days200 Days
DMA Price$18.24$17.61
DMA Trendupup
Distance from DMA-0.9%2.6%
 3M1YR
Volatility60.4%83.4%
Downside Capture311.36258.81
Upside Capture179.82221.98
Correlation (SPY)55.1%34.8%
DYN Betas & Captures as of 5/31/2026

 1M2M3M6M1Y3Y
Beta4.732.922.862.422.451.77
Up Beta4.981.451.482.452.831.48
Down Beta3.151.942.881.741.871.82
Up Capture412%248%438%283%506%954%
Bmk +ve Days13283667141432
Stock +ve Days10203056120370
Down Capture646%683%304%236%179%113%
Bmk -ve Days7132757109318
Stock -ve Days9203266128373

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with DYN
DYN25.5%83.3%0.62-
Sector ETF (XLV)14.4%15.0%0.6924.9%
Equity (SPY)27.2%12.4%1.6634.9%
Gold (GLD)25.8%27.4%0.828.2%
Commodities (DBC)23.3%18.9%0.98-14.2%
Real Estate (VNQ)13.6%13.5%0.6918.6%
Bitcoin (BTCUSD)-37.7%42.4%-1.0019.7%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with DYN
DYN-2.3%79.6%0.32-
Sector ETF (XLV)6.1%14.7%0.2327.7%
Equity (SPY)13.8%17.1%0.6333.6%
Gold (GLD)17.6%18.2%0.783.0%
Commodities (DBC)7.8%19.4%0.30-3.0%
Real Estate (VNQ)2.5%18.8%0.0427.3%
Bitcoin (BTCUSD)12.1%54.2%0.4217.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with DYN
DYN-2.8%78.6%0.29-
Sector ETF (XLV)9.7%16.6%0.4725.8%
Equity (SPY)15.4%18.0%0.7332.7%
Gold (GLD)12.8%16.1%0.662.1%
Commodities (DBC)6.2%18.0%0.27-2.1%
Real Estate (VNQ)5.6%20.7%0.2327.0%
Bitcoin (BTCUSD)60.7%66.8%1.0017.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date5292026
Short Interest: Shares Quantity22.3 Mil
Short Interest: % Change Since 51520266.2%
Average Daily Volume1.5 Mil
Days-to-Cover Short Interest14.6 days
Basic Shares Quantity165.0 Mil
Short % of Basic Shares13.5%

Earnings Returns History

Updated 6/12/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
5/11/20264.8%-1.8%1.8%
3/2/20263.4%-4.9%9.4%
1/12/2026-1.7%-6.0%-3.5%
11/5/2025-12.9%-11.0%6.2%
7/28/2025-1.2%10.1%43.7%
5/8/202520.2%24.5%56.4%
2/27/2025-4.5%-11.7%-14.4%
1/10/2025-31.1%-35.9%-37.2%
...
SUMMARY STATS   
# Positive14810
# Negative91513
Median Positive3.5%7.2%12.0%
Median Negative-4.5%-7.8%-7.4%
Max Positive20.2%24.5%57.1%
Max Negative-31.1%-35.9%-48.5%
 Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
5/11/20264.8%-1.8%1.8%
3/2/20263.4%-4.9%9.4%
1/12/2026-1.7%-6.0%-3.5%
11/5/2025-12.9%-11.0%6.2%
7/28/2025-1.2%10.1%43.7%
5/8/202520.2%24.5%56.4%
2/27/2025-4.5%-11.7%-14.4%
1/10/2025-31.1%-35.9%-37.2%
11/12/20244.3%4.3%-2.3%
3/5/2024-6.6%-7.8%3.8%
10/30/202310.6%24.3%57.1%
8/3/2023-2.2%-10.0%-3.1%
5/11/2023-2.8%-3.0%-7.4%
3/2/20235.1%5.5%-15.0%
11/3/20229.6%0.2%15.8%
8/4/20223.1%8.9%-3.6%
5/2/20223.5%-30.5%-48.5%
3/10/20221.2%0.7%14.6%
11/4/20210.9%-2.5%-10.4%
8/5/20212.7%-10.3%-9.2%
5/6/20211.8%-3.1%1.9%
3/4/2021-5.9%-8.6%-4.4%
11/5/20200.1%-4.8%-1.5%
SUMMARY STATS   
# Positive14810
# Negative91513
Median Positive3.5%7.2%12.0%
Median Negative-4.5%-7.8%-7.4%
Max Positive20.2%24.5%57.1%
Max Negative-31.1%-35.9%-48.5%

SEC Filings

Expand for More
Report DateFiling DateFiling
03/31/202605/11/202610-Q
12/31/202503/02/202610-K
09/30/202511/05/202510-Q
06/30/202507/28/202510-Q
03/31/202505/08/202510-Q
12/31/202402/27/202510-K
09/30/202411/12/202410-Q
06/30/202408/12/202410-Q
03/31/202405/02/202410-Q
12/31/202303/05/202410-K
09/30/202310/30/202310-Q
06/30/202308/03/202310-Q
03/31/202305/11/202310-Q
12/31/202203/02/202310-K
09/30/202211/03/202210-Q
06/30/202208/04/202210-Q
 Collapse to Preview
Report DateFiling DateFiling
03/31/202605/11/202610-Q
12/31/202503/02/202610-K
09/30/202511/05/202510-Q
06/30/202507/28/202510-Q
03/31/202505/08/202510-Q
12/31/202402/27/202510-K
09/30/202411/12/202410-Q
06/30/202408/12/202410-Q
03/31/202405/02/202410-Q
12/31/202303/05/202410-K
09/30/202310/30/202310-Q
06/30/202308/03/202310-Q
03/31/202305/11/202310-Q
12/31/202203/02/202310-K
09/30/202211/03/202210-Q
06/30/202208/04/202210-Q
03/31/202205/02/202210-Q
12/31/202103/10/202210-K
09/30/202111/04/202110-Q
06/30/202108/05/202110-Q
03/31/202105/06/202110-Q
12/31/202003/04/202110-K
09/30/202011/05/202010-Q
06/30/202009/17/2020424B4

Insider Activity

Updated 6/17/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value		Value of
Held Shares		Form
1Friedl-Naderer, JohannaChief Commercial OfficerDirectSell617202618.331452,6582,826,633Form
2Kerr, DouglasChief Medical OfficerDirectSell617202618.3388716,2593,100,611Form
3Cox, JohnCEO & PresidentDirectSell617202618.332,68349,1796,748,208Form
4Posner, Brian S DirectBuy609202616.942,00033,880415,030Form
5Posner, Brian S DirectBuy605202617.482,50043,700393,300Form
 Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value		Value of
Held Shares		Form
1Friedl-Naderer, JohannaChief Commercial OfficerDirectSell617202618.331452,6582,826,633Form
2Kerr, DouglasChief Medical OfficerDirectSell617202618.3388716,2593,100,611Form
3Cox, JohnCEO & PresidentDirectSell617202618.332,68349,1796,748,208Form
4Posner, Brian S DirectBuy609202616.942,00033,880415,030Form
5Posner, Brian S DirectBuy605202617.482,50043,700393,300Form
6Posner, Brian S DirectBuy528202618.212,00036,420364,200Form
7Posner, Brian S DirectBuy522202617.122,50042,800308,160Form
8Friedl-Naderer, JohannaChief Commercial OfficerDirectSell514202618.362284,1862,833,921Form
9Kerr, DouglasChief Medical OfficerDirectSell514202618.361,56428,7153,121,971Form
10Lucera, ErickChief Financial OfficerDirectSell514202618.361,44826,5852,275,263Form
11Cox, JohnCEO & PresidentDirectSell514202618.363,31160,7906,808,512Form
12Rhodes, Jason PSee footnoteSell506202618.1883,2191,512,921144,749Form
13Rhodes, Jason PSee footnoteSell506202618.0311,600209,148151,272Form
14Rhodes, Jason PSee footnoteSell506202618.0011,904214,272152,100Form
15Rhodes, Jason PSee footnoteSell430202618.38227,3374,178,516156,435Form
16Rhodes, Jason PSee footnoteSell427202618.15173,4933,148,898175,728Form
17Rhodes, Jason PSee footnoteSell427202618.48137,9482,549,279195,444Form
18Rhodes, Jason PSee footnoteSell427202619.1973,1081,402,943216,578Form
19Kersten, Dirk See footnoteSell423202620.002,65253,04983,946,148Form
20Kersten, Dirk See footnoteSell423202620.018,300166,12084,045,389Form
21Kersten, Dirk See footnoteSell421202620.07125,2742,513,89884,433,246Form
22Kersten, Dirk See footnoteSell421202620.29211,9744,301,29287,919,424Form
23Kersten, Dirk See footnoteSell417202620.7117,773368,11494,131,173Form
24Kersten, Dirk See footnoteSell417202620.2781,8401,659,04492,491,020Form
25Lucera, ErickChief Financial OfficerDirectSell403202618.645,727106,7512,336,953Form
26Posner, Brian S DirectBuy401202617.082,00034,160264,740Form
27Posner, Brian S DirectBuy313202619.352,00038,700261,225Form
28Kersten, Dirk See footnoteSell313202619.52129,6722,530,56290,635,657Form
29Posner, Brian S DirectBuy310202615.063,00045,180173,190Form
30Friedl-Naderer, JohannaChief Commercial OfficerDirectSell306202614.901482,2052,303,257Form
31Kerr, DouglasChief Medical OfficerDirectSell306202614.9090413,4702,556,929Form
32Cox, JohnCEO & PresidentDirectSell306202614.902,73240,7075,574,760Form
33Cox, JohnCEO & PresidentDirectSell1205202520.722,66255,1574,079,291Form
34Kerr, DouglasChief Medical OfficerDirectSell1205202520.7288018,2341,813,207Form
35Friedl-Naderer, JohannaChief Commercial OfficerDirectSell1205202520.721442,9841,962,785Form
36Cox, JohnCEO & PresidentDirectSell909202513.412,64035,4022,675,818Form
37Friedl-Naderer, JohannaChief Commercial OfficerDirectSell908202513.411441,9311,272,247Form
38Kerr, DouglasChief Medical OfficerDirectSell908202513.4187311,7071,185,310Form
39Friedl-Naderer, JohannaChief Commercial OfficerDirectSell908202513.2789411,8631,260,876Form
40Kerr, DouglasChief Medical OfficerDirectSell908202513.273,55247,1351,184,520Form
41Cox, JohnCEO & PresidentDirectBuy71520259.11100,000911,0002,206,251Form
42Cox, JohnCEO & PresidentDirectSell606202513.354,06054,2011,898,090Form
43Kerr, DouglasChief Medical OfficerDirectSell606202513.351,34217,9161,239,080Form
44Friedl-Naderer, JohannaChief Commercial OfficerDirectSell606202513.351461,9491,280,412Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 6/16/2026